JP2005514440A5 - - Google Patents

Download PDF

Info

Publication number
JP2005514440A5
JP2005514440A5 JP2003559494A JP2003559494A JP2005514440A5 JP 2005514440 A5 JP2005514440 A5 JP 2005514440A5 JP 2003559494 A JP2003559494 A JP 2003559494A JP 2003559494 A JP2003559494 A JP 2003559494A JP 2005514440 A5 JP2005514440 A5 JP 2005514440A5
Authority
JP
Japan
Prior art keywords
aerosol composition
group
medical aerosol
propellant
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003559494A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005514440A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/041251 external-priority patent/WO2003059331A2/en
Publication of JP2005514440A publication Critical patent/JP2005514440A/ja
Publication of JP2005514440A5 publication Critical patent/JP2005514440A5/ja
Withdrawn legal-status Critical Current

Links

JP2003559494A 2001-12-21 2002-12-20 アミドおよび/またはエステルを含有する、賦形剤化合物を含む、医用エアロゾル組成物 Withdrawn JP2005514440A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34262301P 2001-12-21 2001-12-21
PCT/US2002/041251 WO2003059331A2 (en) 2001-12-21 2002-12-20 Medicinal aerosol compositions with an amide and/or ester containing excipient compound

Publications (2)

Publication Number Publication Date
JP2005514440A JP2005514440A (ja) 2005-05-19
JP2005514440A5 true JP2005514440A5 (enExample) 2006-02-09

Family

ID=23342584

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003559494A Withdrawn JP2005514440A (ja) 2001-12-21 2002-12-20 アミドおよび/またはエステルを含有する、賦形剤化合物を含む、医用エアロゾル組成物

Country Status (8)

Country Link
US (1) US7186402B2 (enExample)
EP (1) EP1455764B1 (enExample)
JP (1) JP2005514440A (enExample)
AT (1) ATE406152T1 (enExample)
AU (1) AU2002364594A1 (enExample)
CA (1) CA2470498A1 (enExample)
DE (1) DE60228615D1 (enExample)
WO (1) WO2003059331A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003059331A2 (en) 2001-12-21 2003-07-24 3M Innovative Properties Company Medicinal aerosol compositions with an amide and/or ester containing excipient compound
US20030147814A1 (en) * 2001-12-21 2003-08-07 3M Innovative Properties Company Medicinal aerosol formulations comprising ion pair complexes
DE60231428D1 (de) * 2001-12-21 2009-04-16 3M Innovative Properties Co Medizinische aerosolzusammensetzungen mit einem funktionalisierten polyethylenglykol-hilfsstoff
US20050123484A1 (en) * 2003-10-02 2005-06-09 Collegium Pharmaceutical, Inc. Non-flammable topical anesthetic liquid aerosols
US20060188449A1 (en) * 2003-10-03 2006-08-24 Jane Hirsh Topical aerosol foams
US20050255048A1 (en) * 2004-05-15 2005-11-17 Collegium Pharmaceutical, Inc. Sprayable formulations for the treatment of acute inflammatory skin conditions
GB0614621D0 (en) 2006-07-24 2006-08-30 3M Innovative Properties Co Metered dose dispensers
GB0620700D0 (en) 2006-10-19 2006-11-29 3M Innovative Properties Co Metered dose valves and dispensers
US8652443B2 (en) * 2008-02-14 2014-02-18 Precision Dermatology, Inc. Foamable microemulsion compositions for topical administration
GB201118188D0 (en) 2011-10-21 2011-12-07 3M Innovative Properties Co Manufacture of medicinal aerosol canisters
GB201210580D0 (en) * 2012-06-14 2012-08-01 3M Innovative Properties Co Metered dose dispensing valve
GB201221063D0 (en) 2012-11-23 2013-01-09 3M Innovative Properties Co Metered dose dispensing valve

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
WO1994008599A1 (en) * 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
JP3009924B2 (ja) 1992-12-09 2000-02-14 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 安定化医用エアーゾル溶液製剤
CA2156408C (en) * 1993-03-17 2005-02-15 Daniel C. Duan Aerosol formulation containing a polyester dispersing aid
JPH08507792A (ja) * 1993-03-17 1996-08-20 ミネソタ マイニング アンド マニュファクチャリング カンパニー ジオール−二酸から誘導される分散助剤を含むエーロゾル配合物
US5492688A (en) * 1993-04-28 1996-02-20 The Center For Innovative Technology Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent
DK0731688T3 (da) * 1993-12-02 2003-06-23 Abbott Lab Aerosol-lægemiddelformuleringer til anvendelse med CFC-frie drivmidler
US5508023A (en) * 1994-04-11 1996-04-16 The Center For Innovative Technology Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US6126919A (en) * 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US6218353B1 (en) * 1997-08-27 2001-04-17 Micell Technologies, Inc. Solid particulate propellant systems and aerosol containers employing the same
US6136294C1 (en) * 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
DE69904498T2 (de) * 1998-10-27 2003-04-24 Alcon Laboratories, Inc. Konservierungsmittel für lokale pharmazeutische zubereitungen enthaltend eine fettsäure/aminosäure enthaltende seife
US6258857B1 (en) * 1999-02-04 2001-07-10 Kyowa Industrial Co., Ltd. Internal liquid composition contained as internal liquid in a releasing container and releasing container product
JP2003535122A (ja) 2000-06-02 2003-11-25 ザイコス インク. 生物活性物質のための送達システム
DE60231428D1 (de) * 2001-12-21 2009-04-16 3M Innovative Properties Co Medizinische aerosolzusammensetzungen mit einem funktionalisierten polyethylenglykol-hilfsstoff
US20030147814A1 (en) * 2001-12-21 2003-08-07 3M Innovative Properties Company Medicinal aerosol formulations comprising ion pair complexes
WO2003059331A2 (en) 2001-12-21 2003-07-24 3M Innovative Properties Company Medicinal aerosol compositions with an amide and/or ester containing excipient compound

Similar Documents

Publication Publication Date Title
ES2271642T3 (es) Derivados de tiazol como inhibidores de la fosfodieterasa iv.
RU2363700C2 (ru) Производные хинуклидина и фармацевтические композиции, содержащие их
JP2005514440A5 (enExample)
JP2001526218A5 (enExample)
RU2002123350A (ru) Дипептиднитрильные ингибиторы катепсина К
DK1487829T3 (da) Thiadizolylpiperazinderivater, der er nyttige til behandling eller forebyggelse af smerte
JP2008523098A5 (enExample)
EP0832099A1 (en) Reversible cysteine protease inhibitors
DK1140745T3 (da) Colchinolderivater som vaskulært skadelige midler
JP2005502621A5 (enExample)
JP2006501181A5 (enExample)
NO20060981L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
MY148937A (en) Medicaments with hm74a receptor activity
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
NO20072515L (no) 2-amido-4-fenyltnazolderivater, fremstilling og terapeutsik anvendelse derav
RU2003101319A (ru) Фармацевтическая композиция, обладающая улучшенным противоопухолевым действием и/или сниженными побочными эффектами, содержащая противоопухолевый агент и производное гидроксамовой кислоты
EA200500096A1 (ru) Гетеробиарильные производные в качестве ингибиторов матриксных металлопротеиназ
JPH05201945A (ja) 医薬的に活性なヒドラジン誘導体およびその製造方法
AR065297A1 (es) Formulaciones biodisponibles de compuestos heterociclicos
ES2564144T3 (es) Derivados de 6-[2-(fosfonometoxi)alcoxi] pirimidina que tienen actividad antivírica
RU2003134629A (ru) Соединения цефема
JP2006502086A5 (enExample)
SE0401655D0 (sv) New compounds
CA2589744A1 (en) Pyrrolinidium derivatives as m3 muscarinic receptors
JP2019529501A5 (enExample)